Date Published:
13 February 2009 |
Breast cancer rates fall as women abandon HRT
Breast cancer rates among women in their 50s are falling at the same time as
the number of women under 60 receiving prescriptions for hormone replacement
(HRT) has halved – according to Cancer Research UK.
In 2000 more than 40 per cent of women aged 50-54 were taking HRT and the figure
was more than 35% in the 55-59 age group.
But by 2006 HRT users among 50-54 year olds had plummeted to around 20% and
among 55-59 year olds the percentage dropped to just 15% according to a new
report published online today in the European Journal of Cancer.
Cancer Research UK statisticians have calculated that breast cancer rates among
women aged 50-54 peaked with 5790 women diagnosed with breast cancer in the
UK. But the latest figures for 2005 show a drop in rates of 9%.
In women aged 55-59 rates have varied but overall have fallen by around five
per cent. But among women in their sixties rates between 1999 and 2005 increased
by 24% - which is probably due to the breast cancer screening programme detecting
more tumours.
Women deserted HRT in their droves after research from the Women’s Health
Initiative study in the US and the Million Women Study in the UK found that
using hormone therapy could increase breast cancer risk.
Professor Max Parkin, Cancer Research UK statistician based at Queen Mary College,
University of London and study leader, said:
"Between 1996 and 2000 we can estimate that HRT use was responsible
for an additional breast cancer risk of around 30 per cent to UK women in
their 50s.
But since 2000 there has been a striking decline in the estimated excess
risk of breast cancer in all age groups. Between 1999 and 2005 the risk to
women in their 50s dropped by 14 per cent which represents 1400 fewer cases
in 2005 than would have been expected if HRT use had remained unchanged.
We cannot be absolutely sure that the drop in both breast cancer rates
and breast cancer risk is the direct result of women giving up HRT. But the
parallel is striking and it will be interesting to see if this decline continues
over the next few years."
Further evidence of this parallel was highlighted in the Lancet last week by
Dr David Brewster, director of the Scottish Cancer Registry. He found that the
number of breast cancer cases diagnosed among 50-64 year olds in Scotland fell
from 1470 in 2000 to 1387 in 2005 corresponding to a dramatic drop in HRT prescriptions
by more than 50%.
Dr Lesley Walker, Cancer Research UK's director of cancer information, said:
"We have seen cases of breast cancer increase continually for decades
so it is very positive to learn that incidence of this distressing disease
among women in their 50s is levelling off.
Cancer Research UK’s advice is that women should only take HRT
for medical reasons and for as short a time as possible."
Cancer Research UK
Together with its partners and supporters, Cancer Research UK's vision is
to beat cancer.
*
Cancer Research UK carries out world-class research to improve
understanding of the disease and find out how to prevent, diagnose and treat
different kinds
of cancer.
* Cancer Research UK ensures that its findings are used to improve the lives
of all cancer patients.
* Cancer Research UK helps people to understand cancer, the progress that is
being made and the choices each person can make.
* Cancer Research UK works in partnership with others to achieve the greatest
impact in the global fight against cancer.
For further information about Cancer Research UK's work or to find out how
to support the charity, please call 020 7009 8820 or visit their website (link
at bottom of this page).
News is included on the IvyRose website to inform visitors about current health
issues, but not to endorse any particular view or activity. Any views expressed
in the article above are not necessarily those of IvyRose Ltd.. Material in
this news item was released by Cancer Research UK on 13
February 2009 and may have been edited (e.g. in
style, length, and/or for ease of understanding by our international readers)
for inclusion here. For further information, please visit their website.
  |
